Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1991 Jul;32(1):11–16. doi: 10.1111/j.1365-2125.1991.tb05606.x

Stereoselective pharmacokinetics of oral and intravenous nitrendipine in healthy male subjects.

P A Soons 1, D D Breimer 1
PMCID: PMC1368486  PMID: 1888628

Abstract

1. Stereoselectivity in the pharmacokinetics of nitrendipine was investigated by reanalysing plasma samples of a previously published study (Soons et al., 1989). 2. Racemic nitrendipine was administered intravenously (40 micrograms kg-1) and orally, both as plain tablet (20 mg) and in an osmotic pump device (40 mg Osmet) to nine healthy male subjects. Nitrendipine enantiomers were measured with a stereoselective assay. 3. Upon oral administration (tablet) the bioavailability of (S)-(-)-nitrendipine (13.4% +/- 5.6%) was 75% (50% - 98%) higher than that of (R)-nitrendipine (7.9% +/- 4.0%) (mean +/- s.d. (95% confidence interval)). Values of AUC and Cmax for (S)-nitrendipine were 90% (55% - 121%) and 77% (51% - 100%) higher respectively, than those for (R)-nitrendipine. Similar results were obtained with the osmotic system. 4. The clearance of intravenously administered (S)-nitrendipine was slightly (7%) lower than that of (R)-nitrendipine, but elimination half-lives and volumes of distribution were similar. 5. The difference in disposition of nitrendipine enantiomers is most likely related to a difference in activity of the cytochrome P-450 system towards the enantiomers, giving rise to a two-fold difference in first-pass elimination. 6. Stereoselectivity in the first pass metabolism of nitrendipine exhibited little intersubject variability and therefore is not a major factor in the wide variability in systemic availability of the more-potent (S)-enantiomer.

Full text

PDF
11

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Drayer D. E. Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: an overview. Clin Pharmacol Ther. 1986 Aug;40(2):125–133. doi: 10.1038/clpt.1986.150. [DOI] [PubMed] [Google Scholar]
  2. Eltze M., Boer R., Sanders K. H., Boss H., Ulrich W. R., Flockerzi D. Stereoselective inhibition of thromboxane-induced coronary vasoconstriction by 1,4-dihydropyridine calcium channel antagonists. Chirality. 1990;2(4):233–240. doi: 10.1002/chir.530020408. [DOI] [PubMed] [Google Scholar]
  3. Guengerich F. P., Böcker R. H. Cytochrome P-450-catalyzed dehydrogenation of 1,4-dihydropyridines. J Biol Chem. 1988 Jun 15;263(17):8168–8175. [PubMed] [Google Scholar]
  4. Guengerich F. P. Characterization of human microsomal cytochrome P-450 enzymes. Annu Rev Pharmacol Toxicol. 1989;29:241–264. doi: 10.1146/annurev.pa.29.040189.001325. [DOI] [PubMed] [Google Scholar]
  5. Guengerich F. P., Martin M. V., Beaune P. H., Kremers P., Wolff T., Waxman D. J. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem. 1986 Apr 15;261(11):5051–5060. [PubMed] [Google Scholar]
  6. Jamali F., Mehvar R., Pasutto F. M. Enantioselective aspects of drug action and disposition: therapeutic pitfalls. J Pharm Sci. 1989 Sep;78(9):695–715. doi: 10.1002/jps.2600780902. [DOI] [PubMed] [Google Scholar]
  7. Mikus G., Fischer C., Heuer B., Langen C., Eichelbaum M. Application of stable isotope methodology to study the pharmacokinetics, bioavailability and metabolism of nitrendipine after i.v. and p.o. administration. Br J Clin Pharmacol. 1987 Nov;24(5):561–569. doi: 10.1111/j.1365-2125.1987.tb03214.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Niwa T., Tokuma Y., Nakagawa K., Noguchi H., Yamazoe Y., Kato R. Stereoselective oxidation and plasma protein binding of nilvadipine, a new dihydropyridine calcium antagonist, in man. Res Commun Chem Pathol Pharmacol. 1988 May;60(2):161–172. [PubMed] [Google Scholar]
  9. Richardson P. D., Withrington P. G. Liver blood flow. I. Intrinsic and nervous control of liver blood flow. Gastroenterology. 1981 Jul;81(1):159–173. [PubMed] [Google Scholar]
  10. Rämsch K. D., Graefe K. H., Scherling D., Sommer J., Ziegler R. Pharmacokinetics and metabolism of calcium-blocking agents nifedipine, nitrendipine, and nimodipine. Am J Nephrol. 1986;6 (Suppl 1):73–80. doi: 10.1159/000167224. [DOI] [PubMed] [Google Scholar]
  11. Soons P. A., Breimer D. D. Gas chromatographic analysis of nitrendipine and its pyridine metabolite in human plasma. J Chromatogr. 1988 Jul 15;428(2):362–368. doi: 10.1016/s0378-4347(00)83929-8. [DOI] [PubMed] [Google Scholar]
  12. Soons P. A., Roosemalen M. C., Breimer D. D. Enantioselective determination of felodipine and other chiral dihydropyridine calcium entry blockers in human plasma. J Chromatogr. 1990 Jun 29;528(2):343–356. doi: 10.1016/s0378-4347(00)82393-2. [DOI] [PubMed] [Google Scholar]
  13. Soons P. A., de Boer A. G., van Brummelen P., Breimer D. D. Oral absorption profile of nitrendipine in healthy subjects: a kinetic and dynamic study. Br J Clin Pharmacol. 1989 Feb;27(2):179–189. doi: 10.1111/j.1365-2125.1989.tb05349.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Tokuma Y., Fujiwara T., Noguchi H. Plasma levels of (+)- and (-)-nilvadipine after oral dosing with racemic (+)-nilvadipine in man. Res Commun Chem Pathol Pharmacol. 1987 Aug;57(2):229–237. [PubMed] [Google Scholar]
  15. de Waziers I., Cugnenc P. H., Yang C. S., Leroux J. P., Beaune P. H. Cytochrome P 450 isoenzymes, epoxide hydrolase and glutathione transferases in rat and human hepatic and extrahepatic tissues. J Pharmacol Exp Ther. 1990 Apr;253(1):387–394. [PubMed] [Google Scholar]
  16. van Harten J., Burggraaf J., Danhof M., van Brummelen P., Breimer D. D. The contribution of nisoldipine-induced changes in liver blood flow to its pharmacokinetics after oral administration. Br J Clin Pharmacol. 1989 May;27(5):581–586. doi: 10.1111/j.1365-2125.1989.tb03420.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES